Filgotinib information

Filgotinib
Clinical data
Trade names	Jyseleca
Other names	GLPG0634, GS-6034
License data	EU EMA: by INN;
Routes of; administration	By mouth
Drug class	Janus kinase inhibitor
ATC code	L04AF04 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Elimination half-life	6 hours
Identifiers
	IUPAC name N-[5-[4-[(1,1-Dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide;
CAS Number	1206161-97-8 ;
PubChem CID	49831257;
IUPHAR/BPS	7913;
DrugBank	DB14845 ;
ChemSpider	28189566 ;
UNII	3XVL385Q0M;
KEGG	D10871 ; as salt: D11106 ;
ChEMBL	ChEMBL3301607 ;
PDB ligand	2HB (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID80152935 ;
Chemical and physical data
Formula	C21H23N5O3S
Molar mass	425.51 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1;
	InChI InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27) ; Key:RIJLVEAXPNLDTC-UHFFFAOYSA-N ;
	(what is this?) (verify)

Filgotinib, sold under the brand name Jyseleca, is a medication used for the treatment of rheumatoid arthritis (RA).^[3] It was developed by the Belgian-Dutch biotech company Galapagos NV.^[6]

The most common side effects include nausea (feeling sick), upper respiratory tract infection (nose and throat infection), urinary tract infection and dizziness.^[3]

Filgotinib was approved for medical use in both the European Union and Japan in September 2020.^[3]^[6]^[7]

^ "Pipeline". Gilead Sciences. 27 July 2020. Retrieved 27 July 2020.
^ "Jyseleca 100 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 1 October 2020. Retrieved 4 October 2020.
^ ^a ^b ^c ^d "Jyseleca EPAR". European Medicines Agency (EMA). 26 May 2020. Retrieved 4 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ "Jyseleca Product information". Union Register of medicinal products. Retrieved 3 March 2023.
^ Namour F, Diderichsen PM, Cox E, Vayssière B, Van der Aa A, Tasset C, et al. (August 2015). "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection". Clinical Pharmacokinetics. 54 (8): 859–74. doi:10.1007/s40262-015-0240-z. PMC 4513223. PMID 25681059.
^ ^a ^b "European Commission Grants Marketing Authorization for Jyseleca (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis" (Press release). Gilead Sciences. 25 September 2020. Retrieved 4 October 2020 – via Business Wire.
^ "Jyseleca (Filgotinib) Approved in Japan for Rheumatoid Arthritis". Gilead Sciences. 25 September 2020. Retrieved 4 October 2020 – via Business Wire.

[1] "Pipeline". Gilead Sciences. 27 July 2020. Retrieved 27 July 2020.

[2] "Jyseleca 100 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 1 October 2020. Retrieved 4 October 2020.

[Jyseleca_EPAR-3] "Jyseleca EPAR". European Medicines Agency (EMA). 26 May 2020. Retrieved 4 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[4] "Jyseleca Product information". Union Register of medicinal products. Retrieved 3 March 2023.

[Namour-5] Namour F, Diderichsen PM, Cox E, Vayssière B, Van der Aa A, Tasset C, et al. (August 2015). "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection". Clinical Pharmacokinetics. 54 (8): 859–74. doi:10.1007/s40262-015-0240-z. PMC 4513223. PMID 25681059.

[Gilead_PR_20200925-6] "European Commission Grants Marketing Authorization for Jyseleca (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis" (Press release). Gilead Sciences. 25 September 2020. Retrieved 4 October 2020 – via Business Wire.

[Gilead_PR_20200924-7] "Jyseleca (Filgotinib) Approved in Japan for Rheumatoid Arthritis". Gilead Sciences. 25 September 2020. Retrieved 4 October 2020 – via Business Wire.

Filgotinib information

and 25 Related for: Filgotinib information

Filgotinib

Galapagos NV

Janus kinase inhibitor

Janus kinase

Erythropoietin

Cytokine

ATC code L04

Etanercept

Ruxolitinib

Adipokine

Inflammatory cytokine

Cucurbitacin

Upadacitinib

Tofacitinib

Interferon type I

Interferon alfa

TNF inhibitor

Ulcerative colitis

Eltrombopag

Denosumab

Baricitinib

Deucravacitinib

Lymphokine

Darbepoetin alfa

Macrophage inflammatory protein